Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis

Yanan Zhao, Padmaja Paderu, Radha Railkar, Cameron Douglas, Robert Iannone, Norah Shire, David S. Perlin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A critical challenge for the successful application of antifungal therapies for invasive aspergillosis (IA) is a lack of reliable biomarkers to assess early treatment response. Patients with proven or probable IA were prospectively enrolled, and serial blood samples were collected at 8 specified time points during 12-week antifungal therapy. Total nucleic acid was extracted from 2.5 ml blood and tested for Aspergillus-specific RNA by a pan- Aspergillus real-time nucleic acid sequence-based amplification (NASBA) assay. Serum 1, 3-β-D-glucan (BG) and galactomannan (GM) were measured in parallel. Clinical outcome was evaluated at 6 and 12 weeks. Overall, 48/328 (14.6%) blood samples from 29/46 (63%) patients had positive NASBA detection at baseline and/or some point during the study. Positive NASBA results during the first 4 and 6 weeks of treatment are significantly associated with the 12-week outcome. Blood RNA load change during weeks 4-6 may be informative to predict outcome at 12 weeks. While independent of serum GM, the kinetic change of circulating Aspergillus RNA appears to be well correlated with that of BG on some patient individuals.Monitoring blood Aspergillus RNA during the first 4-6 weeks of antifungal treatment may help assess therapeutic response. Combination of circulating Aspergillus RNA and BG may be a useful adjunct to assess response.

Original languageEnglish (US)
Pages (from-to)801-807
Number of pages7
JournalMedical mycology
Volume54
Issue number8
DOIs
StatePublished - Nov 1 2016

Fingerprint

Aspergillosis
Aspergillus
Self-Sustained Sequence Replication
Biomarkers
RNA
Therapeutics
Serum
Nucleic Acids

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Keywords

  • Antifungal therapy
  • Aspergillus RNA
  • Biomarker
  • Invasive aspergillosis
  • NASBA

Cite this

Zhao, Yanan ; Paderu, Padmaja ; Railkar, Radha ; Douglas, Cameron ; Iannone, Robert ; Shire, Norah ; Perlin, David S. / Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis. In: Medical mycology. 2016 ; Vol. 54, No. 8. pp. 801-807.
@article{db2fb9f472024477bec7010436aa0133,
title = "Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis",
abstract = "A critical challenge for the successful application of antifungal therapies for invasive aspergillosis (IA) is a lack of reliable biomarkers to assess early treatment response. Patients with proven or probable IA were prospectively enrolled, and serial blood samples were collected at 8 specified time points during 12-week antifungal therapy. Total nucleic acid was extracted from 2.5 ml blood and tested for Aspergillus-specific RNA by a pan- Aspergillus real-time nucleic acid sequence-based amplification (NASBA) assay. Serum 1, 3-β-D-glucan (BG) and galactomannan (GM) were measured in parallel. Clinical outcome was evaluated at 6 and 12 weeks. Overall, 48/328 (14.6{\%}) blood samples from 29/46 (63{\%}) patients had positive NASBA detection at baseline and/or some point during the study. Positive NASBA results during the first 4 and 6 weeks of treatment are significantly associated with the 12-week outcome. Blood RNA load change during weeks 4-6 may be informative to predict outcome at 12 weeks. While independent of serum GM, the kinetic change of circulating Aspergillus RNA appears to be well correlated with that of BG on some patient individuals.Monitoring blood Aspergillus RNA during the first 4-6 weeks of antifungal treatment may help assess therapeutic response. Combination of circulating Aspergillus RNA and BG may be a useful adjunct to assess response.",
keywords = "Antifungal therapy, Aspergillus RNA, Biomarker, Invasive aspergillosis, NASBA",
author = "Yanan Zhao and Padmaja Paderu and Radha Railkar and Cameron Douglas and Robert Iannone and Norah Shire and Perlin, {David S.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1093/mmy/myw043",
language = "English (US)",
volume = "54",
pages = "801--807",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "8",

}

Zhao, Y, Paderu, P, Railkar, R, Douglas, C, Iannone, R, Shire, N & Perlin, DS 2016, 'Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis', Medical mycology, vol. 54, no. 8, pp. 801-807. https://doi.org/10.1093/mmy/myw043

Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis. / Zhao, Yanan; Paderu, Padmaja; Railkar, Radha; Douglas, Cameron; Iannone, Robert; Shire, Norah; Perlin, David S.

In: Medical mycology, Vol. 54, No. 8, 01.11.2016, p. 801-807.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis

AU - Zhao, Yanan

AU - Paderu, Padmaja

AU - Railkar, Radha

AU - Douglas, Cameron

AU - Iannone, Robert

AU - Shire, Norah

AU - Perlin, David S.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - A critical challenge for the successful application of antifungal therapies for invasive aspergillosis (IA) is a lack of reliable biomarkers to assess early treatment response. Patients with proven or probable IA were prospectively enrolled, and serial blood samples were collected at 8 specified time points during 12-week antifungal therapy. Total nucleic acid was extracted from 2.5 ml blood and tested for Aspergillus-specific RNA by a pan- Aspergillus real-time nucleic acid sequence-based amplification (NASBA) assay. Serum 1, 3-β-D-glucan (BG) and galactomannan (GM) were measured in parallel. Clinical outcome was evaluated at 6 and 12 weeks. Overall, 48/328 (14.6%) blood samples from 29/46 (63%) patients had positive NASBA detection at baseline and/or some point during the study. Positive NASBA results during the first 4 and 6 weeks of treatment are significantly associated with the 12-week outcome. Blood RNA load change during weeks 4-6 may be informative to predict outcome at 12 weeks. While independent of serum GM, the kinetic change of circulating Aspergillus RNA appears to be well correlated with that of BG on some patient individuals.Monitoring blood Aspergillus RNA during the first 4-6 weeks of antifungal treatment may help assess therapeutic response. Combination of circulating Aspergillus RNA and BG may be a useful adjunct to assess response.

AB - A critical challenge for the successful application of antifungal therapies for invasive aspergillosis (IA) is a lack of reliable biomarkers to assess early treatment response. Patients with proven or probable IA were prospectively enrolled, and serial blood samples were collected at 8 specified time points during 12-week antifungal therapy. Total nucleic acid was extracted from 2.5 ml blood and tested for Aspergillus-specific RNA by a pan- Aspergillus real-time nucleic acid sequence-based amplification (NASBA) assay. Serum 1, 3-β-D-glucan (BG) and galactomannan (GM) were measured in parallel. Clinical outcome was evaluated at 6 and 12 weeks. Overall, 48/328 (14.6%) blood samples from 29/46 (63%) patients had positive NASBA detection at baseline and/or some point during the study. Positive NASBA results during the first 4 and 6 weeks of treatment are significantly associated with the 12-week outcome. Blood RNA load change during weeks 4-6 may be informative to predict outcome at 12 weeks. While independent of serum GM, the kinetic change of circulating Aspergillus RNA appears to be well correlated with that of BG on some patient individuals.Monitoring blood Aspergillus RNA during the first 4-6 weeks of antifungal treatment may help assess therapeutic response. Combination of circulating Aspergillus RNA and BG may be a useful adjunct to assess response.

KW - Antifungal therapy

KW - Aspergillus RNA

KW - Biomarker

KW - Invasive aspergillosis

KW - NASBA

UR - http://www.scopus.com/inward/record.url?scp=84994589928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994589928&partnerID=8YFLogxK

U2 - 10.1093/mmy/myw043

DO - 10.1093/mmy/myw043

M3 - Article

C2 - 27335056

AN - SCOPUS:84994589928

VL - 54

SP - 801

EP - 807

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 8

ER -

Zhao Y, Paderu P, Railkar R, Douglas C, Iannone R, Shire N et al. Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis. Medical mycology. 2016 Nov 1;54(8):801-807. https://doi.org/10.1093/mmy/myw043